Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | 2025-10-16 19:38:35 | 4.09 | 0.13 | 3.28 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDIT | 0001650664 | Editas Medicine, Inc. | US28106W1036 | 5299000AON4Q9NT2JE42 | 464097528 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 11 HURLEY ST. | CAMBRIDGE | MA | 02141 | UNITED STATES | US | 617-401-9000 | 11 HURLEY ST., CAMBRIDGE, MA, 02141 | 11 HURLEY ST., CAMBRIDGE, MA, 02141 | — | Biotechnology | 2013 | Gilmore O'Neill | 226 | http://editasmedicine.com | 383,847,152 | 87,388,425 | 89,920,164 | Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. | 2025-10-10 22:07:00 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 383,847,152 | -287,280,847 | -42.8057 | 82,976,284 | 1,162,434 | 1.4208 |
| 2023 | 671,127,999 | 37,321,352 | 5.8884 | 81,813,850 | 12,843,662 | 18.622 |
| 2022 | 633,806,647 | -513,529,526 | -44.7584 | 68,970,188 | 451,217 | 0.6585 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Baisong Mei | Chief Medical Officer, Executive Vice President | 2024 | 492,327 | — | 75,332 | 243,000 | 8,900 | 821,402 |
| Erick Lucera | Chief Financial Officer, Executive Vice President | 2024 | 482,600 | — | 350,176 | 234,544 | 8,290 | 1,809,321 |
| Gilmore O’Neill | Chief Executive Officer, President | 2024 | 667,100 | — | 1,296,544 | 440,286 | 8,900 | 5,126,868 |
| Baisong Mei | Chief Medical Officer, Senior Vice President | 2023 | 459,930 | 0 | 156,960 | 186,995 | 7,980 | 1,141,405 |
| Erick Lucera | Chief Financial Officer, Executive Vice President | 2023 | 285,615 | 0 | 748,619 | 146,076 | 794 | 2,215,616 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 246 |
| 2023 | 265 |
| 2022 | 226 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 32,314,000 | 78,123,000 | 19,712,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 199,247,000 | 177,651,000 | 174,958,000 |
| General And Administrative Expenses | 71,987,000 | 69,653,000 | 70,704,000 |
| Operating Expenses | 283,466,000 | 247,304,000 | 245,662,000 |
| Operating Income | -251,152,000 | -169,181,000 | -225,950,000 |
| Net Income | -237,093,000 | -153,219,000 | -220,432,000 |
| Earnings Per Share Basic | -2.88 | -2.02 | -3.21 |
| Earnings Per Share Diluted | -2.88 | -2.02 | -3.21 |
| Weighted Average Shares Outstanding Basic | 82,338,220 | 75,965,633 | 68,664,822 |
| Weighted Average Shares Outstanding Diluted | 82,338,220 | 75,965,633 | 68,664,822 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 131,541,000 | 123,652,000 | 141,522,000 |
| Marketable Securities Current | 138,372,000 | 199,459,000 | 202,752,000 |
| Accounts Receivable | 16,266,000 | 10,187,000 | 5,145,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 289,315,000 | 340,829,000 | 356,754,000 |
| Marketable Securities Non Current | 0 | 104,024,000 | 93,097,000 |
| Property Plant And Equipment | 14,497,000 | 12,032,000 | 15,569,000 |
| Other Assets Non Current | 5,223,000 | 8,588,000 | 5,253,000 |
| Total Assets Non Current | 52,274,000 | 158,324,000 | 157,567,000 |
| Total Assets | 341,589,000 | 499,153,000 | 514,321,000 |
| Accounts Payable | 5,493,000 | 8,269,000 | 9,511,000 |
| Deferred Revenue | 6,221,000 | 8,221,000 | 8,221,000 |
| Short Term Debt | 5,000,000 | — | — |
| Other Liabilities Current | 45,859,000 | 34,563,000 | 31,296,000 |
| Total Liabilities Current | 77,225,000 | 63,217,000 | 60,110,000 |
| Long Term Debt | 57,434,000 | — | — |
| Other Liabilities Non Current | 3,072,000 | 1,800,000 | — |
| Total Liabilities Non Current | 130,090,000 | 86,839,000 | 93,531,000 |
| Total Liabilities | 207,315,000 | 150,056,000 | 153,641,000 |
| Common Stock | 8,000 | 8,000 | 7,000 |
| Retained Earnings | -1,468,443,000 | -1,231,350,000 | -1,078,131,000 |
| Accumulated Other Comprehensive Income | 268,000 | 198,000 | -3,601,000 |
| Total Shareholders Equity | 134,274,000 | 349,097,000 | 360,680,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 5,809,000 | 6,064,000 | 6,337,000 |
| Share Based Compensation Expense | 21,417,000 | 19,798,000 | 29,294,000 |
| Other Non Cash Income Expense | 415,000 | -1,596,000 | 724,000 |
| Change In Accounts Receivable | 6,079,000 | 5,042,000 | 4,878,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -2,286,000 | -1,492,000 | 4,368,000 |
| Change In Other Liabilities | 1,271,000 | 1,800,000 | 10,505,000 |
| Cash From Operating Activities | -210,284,000 | -132,178,000 | -177,349,000 |
| Purchases Of Marketable Securities | 86,217,000 | 258,517,000 | 315,186,000 |
| Sales Of Marketable Securities | 257,189,000 | 259,505,000 | 433,354,000 |
| Acquisition Of Property Plant And Equipment | 8,826,000 | 4,719,000 | 4,118,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 162,146,000 | -3,731,000 | 114,068,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 0 | 0 | 0 |
| Issuance Of Common Stock | 0 | 117,079,000 | 979,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 56,027,000 | 118,039,000 | 1,284,000 |
| Change In Cash | 7,889,000 | -17,870,000 | -61,997,000 |
| Cash At End Of Period | 131,541,000 | 123,652,000 | 141,522,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -2.88 | -2.02 | -3.21 |
| Price To Earnings Ratio | -0.441 | -5.0149 | -2.7632 |
| Earnings Growth Rate | 42.5743 | -37.0717 | 12.6316 |
| Price Earnings To Growth Ratio | -0.0104 | 0.1353 | -0.2188 |
| Book Value Per Share | 1.6308 | 4.5955 | 5.2528 |
| Price To Book Ratio | 0.7788 | 2.2043 | 1.6886 |
| Ebitda | -229,156,000 | -147,155,000 | -214,095,000 |
| Enterprise Value | 35,462,539.4 | — | — |
| Dividend Yield | 0 | 0 | 0 |
| Dividend Payout Ratio | 0 | 0 | 0 |
| Debt To Equity Ratio | 0.465 | — | — |
| Capital Expenditures | 8,274,000 | 2,527,000 | 4,788,000 |
| Free Cash Flow | -218,558,000 | -134,705,000 | -182,137,000 |
| Return On Equity | -1.7657 | -0.4389 | -0.6112 |
| One Year Beta | 1.8885 | 1.7279 | 2.1949 |
| Three Year Beta | 2.0417 | 2.0348 | 1.5786 |
| Five Year Beta | 1.6091 | 1.6405 | 1.6516 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| O'Neill Gilmore Neil | Director, CEO | 2025-09-03 | 5,592 | D | 274,690 |
| Parison Amy | SVP, Chief Financial Officer | 2025-09-03 | 458 | D | 16,369 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 2025-09-03 | 710 | D | 69,490 |
| Parison Amy | SVP, Chief Financial Officer | 2025-08-07 | 679 | D | 16,827 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 2025-07-31 | 5,121 | D | 64,398 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| James M Inhofe | Senator | 2019-12-20 | Sale (Full) | 2019-02-04 | Self | $15,001 - $50,000 |
| James M Inhofe | Senator | 2019-02-25 | Sale (Full) | 2019-02-04 | Self | $15,001 - $50,000 |
| James M Inhofe | Senator | 2017-11-08 | Purchase | 2017-10-19 | Self | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Daniel Goldman | 2023-05-19 | NY10 | Sale | 2023-04-10 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| TRUST CO OF TOLEDO NA /OH/ | 2025-09-30 | 1,735 | 500 | 3.47 |
| CWM, LLC | 2025-09-30 | 155,000 | 44,628 | 3.4732 |
| Green Alpha Advisors, LLC | 2025-09-30 | 508,050 | 146,412 | 3.47 |
| Farther Finance Advisors, LLC | 2025-09-30 | 3,949 | 1,138 | 3.4701 |
| DLK Investment Management, LLC | 2025-09-30 | 101,737 | 29,319 | 3.47 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 369 | 926.19 | 0.0004 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 23,855 | 59,876.05 | 0.0025 |
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 43,971 | 110,367.21 | 0.0084 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Total Market Index Fund | FZROX | 33,611 | 84,363.61 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Extended Market Index Fund | FZIPX | 22,301 | 55,975.51 | 0.0031 |